In other words, this healthcare stock looks risky right now and is, at this point, unlikely to make investors rich over the ...

Biogen (BIIB) stock gains as Piper Sandler upgrades the company, citing positives in the company’s recent deal to acquire eye ...

Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of t ...

Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial ...

The S&P 500 (SP500) closed in the green on Friday after the week saw Iran declaring the Strait of Hormuz open for commercial vessels, along with earnings reports from streaming pioneer Netflix and ...

Biogen, TE Connectivity and ZTO Express gain attention as broker upgrades and solid earnings growth position them for potential upside in a record-high market.

Biogen has agreed to acquire ​Apellis ​Pharmaceuticals ​for about $5.6 billion in cash, expanding its portfolio ⁠of ‌rare-disease medicines.

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...

Biogen said Tuesday that it would buy Apellis Pharmaceuticals for an upfront payment of around $5.6 billion, expanding its portfolio with a set of approved immunology drugs. Cambridge-based Biogen ...

"HI-Bio was really the key catalyst to bring us back to California," a Biogen executive said of its new South San Francisco ...

Biogen, already developing a drug that can be used to treat several kidney disorders, is paying a large premium for Apellis ...

Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will ...